氨氯地平与厄贝沙坦对原发性高血压患者血清基质金属蛋白酶的影响

Effect of amlodipine and irbesartan on serum tissue inhibitor of metalloproteinases in patients with hypertension

目的探讨长效二氢吡啶类降压药物氨氯地平及ARB类降压药物厄贝沙坦对高血压病患者血浆炎性介质超敏C反应蛋白(hs-CRP)、MMP-9、1-型组织基质金属蛋白酶抑制物(TIMP-1)浓度的影响。方法将66例高血压病患者随机双盲分为氨氯地平组(33例)和厄贝沙坦组(33例),两组经过2周的药物洗脱期后,分别给予8周的氨氯地平(5～10mg/d)或厄贝沙坦(150～300mg/d)治疗,在治疗前后对血压情况及hs-CRP、TIMP-1进行监测。结果两组患者治疗后收缩压和舒张压均显著下降,血压达标率分别为77.6%和80.4%。氨氯地平组hs-CRP治疗前后分别为(5.28±3.14)mg/L、(2.19±1.70)mg/L,厄贝沙坦组分别为(5.84±2.58)mg/L、(1.99±0.94)mg/L;氨氯地平组TIMP-1治疗前后分别为(63.71±36.21)ng/mL、(59.12±31.88)ng/mL,厄贝沙坦组分别为(66.89±37.69)ng/mL、(55.69±26.97)ng/mL,均显著下降(均P<0.05)。结论氨氯地平和厄贝沙坦对高血压病患者在有效降压的同时,均能降低血浆中炎性介质hs-CRP、MMP-9和TIMP-1的含量,可能在一定程度上降低高血压靶器官的损伤。

【Objective】To observe the influence of amlodipine and irbesartan on serum matrix metalloproteinases-9（MMP-9）,tissue inhibitor of metalloproteinases-1（TIMP-1） and hs-CRP in patients with hypertension.【Methods】 66 patients with HBP were stratified by randomized,contrastive assigned to amlodipine group（5 mg/d of amlodipine for8weeks）,irbesartan group（150 mg/d of irbesartan for 8 weeks）.The serum levels of MMP-9,TIMP-1,hsCRP before and after treatment were detected.【Results】After treatment of drugs,the levels of serum MMP-9,TIMP-1 and hs-CRP were significantly decreased（P 0.01）.【Conclusion】Amlodipine and irbesartan could adjust the levels of MMPs,TIMPs and hs-CRP in patients with hypertension,which might reduce direct effect on the relieving target organ damage.